CorMedix Inc
NASDAQ:CRMD

Watchlist Manager
CorMedix Inc Logo
CorMedix Inc
NASDAQ:CRMD
Watchlist
Price: 7.75 USD Market Closed
Market Cap: $610.6m

Operating Margin

48.5%
Current
Improving
by 34 384.3%
vs 3-y average of -34 335.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
48.5%
=
Operating Income
$104m
/
Revenue
$214.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
48.5%
=
Operating Income
$104m
/
Revenue
$214.3m

Peer Comparison

Country Company Market Cap Operating
Margin
US
CorMedix Inc
NASDAQ:CRMD
617.4m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

Higher than 96% of companies in the United States of America
Percentile
96th
Based on 14 112 companies
96th percentile
48.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

CorMedix Inc
Glance View

CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.

CRMD Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
48.5%
=
Operating Income
$104m
/
Revenue
$214.3m
What is CorMedix Inc's current Operating Margin?

The current Operating Margin for CorMedix Inc is 48.5%, which is above its 3-year median of -34 335.8%.

How has Operating Margin changed over time?

Over the last 3 years, CorMedix Inc’s Operating Margin has increased from -30 010% to 48.5%. During this period, it reached a low of -138 933.3% on Sep 30, 2023 and a high of 48.5% on Oct 30, 2025.

Back to Top